NTLA

#2071
Intellia Therapeutics, Inc
14.7000 USD
+3.09%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
14.6400
14.7750
1年のレンジ
7.9500
17.0900
1日の変化
+3.09%
月次変化
+12.04%
6か月変化
+7.14%
1年の変化
+7.14%
以前の終値
14.2600
始値
14.7600
Bid
Ask
安値
14.6400
High
14.7750
ボリューム
192
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 1.7366 B
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-2.36
売上高対価格比率
14.4

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

ニュース